Bli medlem
Bli medlem

Du är här


AstraZeneca: AstraZeneca highlights continued progress of oncology pipeline at ASCO 2016 - Leadership in DNA damage response therapies

73 abstracts presented at ASCO with 19 related to Lynparza and new
potential medicines targeting DNA damage response in multiple tumour

Continued momentum of immuno-oncology medicines including new data on
durvalumab in bladder cancer, underpinning the Breakthrough Therapy
Designation, and new data in first-line NSCLC

Further insights on Tagrisso's ability to penetrate the blood-brain
barrier in patients with metastatic lung cancer, and acalabrutinib in
chronic lymphocytic leukaemia

AstraZeneca and its global biologics research and development arm,
MedImmune, will provide an update on their extensive oncology
pipeline at the annual meeting of the American Society of Clinical
Oncology (ASCO) in Chicago, USA, on 3-7 June 2016.

Highlights will include new data demonstrating the strength and
versatility of AstraZeneca's industry-leading line of DNA damage
response (DDR) medicines in multiple types of cancer. New data will
highlight the continued momentum behind AstraZeneca's numerous
immuno-oncology (IO) programmes, and showcase small-molecule
developments including Tagrisso (osimertinib) in leptomeningeal
(brain) disease and the highly-selective Bruton's tyrosine kinase
(BTK) inhibitor, acalabrutinib, in chronic lymphocytic leukaemia

Sean Bohen, Executive Vice President, Global Medicines Development and
Chief Medical Officer at AstraZeneca, said: "Oncology is a strategic
priority for AstraZeneca because of the potential of our broad
pipeline to offer transformational therapies in cancer care. At ASCO,
we will update on our next-generation portfolio focusing on DNA
damage response as a breakthrough paradigm in cancer treatment,
including new long-term overall survival data for Lynparza. Our
increased commitment to DDR therapies complements developments in our
exciting immuno-oncology pipeline, from which we are expecting
clinical results over the coming year."

DDR: A promising scientific platform, a leading position for

DDR is a term describing the network of cellular pathways that
minimise the daily impact of DNA damage. Currently, many cancers are
known to have defects in DDR pathways, which makes them dependent on
and therefore, highly sensitive to inhibition of the remaining DDR
pathways. Targeting DDR deficiencies to preferentially kill cancer
cells, while minimising the impact on normal cells, has potential for
more selective, better tolerated therapies to improve survival in
multiple cancers.

AstraZeneca is developing a comprehensive pipeline of compounds that
target molecular pathways across the DDR system. These include the
PARP inhibitor Lynparza (olaparib); Wee1 inhibitor AZD1775, ATM
inhibitor AZD0156; ATR inhibitor AZD6738, and Aurora B Kinase
inhibitor AZD2811. These compounds act on different cell-cycle points
to prevent tumour cells from reproducing.

At the ASCO congress, DDR presentations will highlight:

· The potential for maintenance of DDR therapies as shown by
Lynparza overall survival data from Study 19 in ovarian cancer
(Abstract # 5501). This abstract has been selected as a "Best of
ASCO" abstract.

· Opportunities for combination approaches with DDR and
immuno-oncology therapies as shown in a Phase I study of the PD-L1
inhibitor, durvalumab, in combination with Lynparza or a VEGFR
inhibitor, cediranib, in women's cancers (Abstract # 3015)

· The importance of selecting patients with a DDR pathway defect
using the right diagnostic tool (abstract #4041)

· The potential of DDR therapies against multiple biological DDR
targets in different tumour types, with studies of the
highly-selective WEE1 inhibitor, AZD1775, in advanced high-grade
serous ovarian cancer (Abstract # TPS5610), squamous cell carcinoma
of the head and neck (SCCHN) (Abstract # TPS6106), advanced solid
tumours (Abstract # TPS2608) and glioblastoma (GBM) (Abstract # 2008)

Immuno-Oncology: Robust development momentum on track for read-outs in
H1 2017

AstraZeneca is leading in a number of first-line studies with its IO
strategy, where combined PD-L1 and CTLA-4 blockade - through the
combination of durvalumab and tremelimumab - may address a
significant unmet medical need for cancer patients who may not
benefit from PD-1 pathway drugs in monotherapy.

Key updates include presentations covering pre-clinical data,
late-stage trials and biomarker research:

· Early study results of durvalumab monotherapy in urothelial
bladder cancer from Phase Ib Study 1108 (Abstract # 4502)

· Final results from a Phase III study of tremelimumab in
mesothelioma (Abstract # 8502)

· New study results on safety and clinical activity of durvalumab as
first-line treatment in non-small cell lung cancer (NSCLC) (Abstract
# 9029)

· Ongoing investigation of the potential synergistic effects of
durvalumab and the CTLA-4 inhibitor, tremelimumab, in bladder cancer
(DANUBE trial - Abstract # TPS4574) and SCCHN (KESTREL trial -
Abstract # TPS6101)

· Enhanced understanding of PD-L1 biomarker expression in relation
to primary versus metastatic tumours and sample age (Abstract # 3025)

Tagrisso in brain metastasis; acalabrutinib in CLL

AstraZeneca's strong heritage in developing innovative targeted small
molecules was underscored by the recent approval of Tagrisso as the
first indicated treatment for EGFR T790M mutation-positive metastatic
NSCLC in the US, EU and Japan. At ASCO, new data will highlight the
importance of Tagrisso activity in leptomeningeal disease through its
ability to penetrate the blood-brain barrier. Further presentations
will show the growing role of circulating tumour DNA (ctDNA) testing
for diagnosis and treatment monitoring.

Key updates will also include presentation on the potential of our
potent, highly-selective BTK inhibitor, acalabrutinib, in chronic
lymphocytic leukaemia (CLL):

· Data from the BLOOM study of Tagrisso in patients with
leptomeningeal disease as a complication of EGFRm-metastatic NSCLC
(Abstract # 9002)

· Intensive plasma ctDNA profiling in experimental trials to
identify markers of acquired drug resistance (Abstract # 11530)

· Acalabrutinib - preliminary results from a first-line study as
first-line therapy in CLL (Abstract # 7521) and in a Phase II study
in combination with pembrolizumab in metastatic pancreatic cancer
(Abstract # 4130)

To download additional supporting material including abstract chart,
animations, video and infographics please visit AstraZeneca ASCO 2016

Supporting material covers:

DDR · IO · Ovarian · Lung

- ENDS -


A Media Briefing on Saturday, 4 June 2016, 18:00-19:00 CDT, at the
Hyatt Regency (room Columbus I-J) will update journalists on latest
advances in AstraZeneca's oncology portfolio being reported at ASCO.
In addition, the briefing will focus on the potential of DDR
therapies as a breakthrough paradigm in cancer treatment.

If you are interested to attend, please contact:

· Neil Burrows (; +44 7842 350541)
· Karen Birmingham (; +44 7818

An Investor science event on Monday, 6 June 2016, 19:00-20:30 CDT will
highlight the continuing momentum behind new developments in
AstraZeneca's Oncology therapy area.

Investors and analysts wishing to attend are invited to register here
or contact the Investor Relations Team (details below).

About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a
quickly growing portfolio of new medicines that has the potential to
transform patients' lives and the Company's future. With at least 6
new medicines to be launched between 2014 and 2020 and a broad
pipeline of small molecules and biologics in development, we are
committed to advance New Oncology as one of AstraZeneca's six Growth
Platforms focused on lung, ovarian, breast and blood cancers. In
addition to our core capabilities, we actively pursue innovative
partnerships and investments that accelerate the delivery of our
strategy, as illustrated by our investment in Acerta Pharma in

By harnessing the power of four scientific platforms --
immuno-oncology, the genetic drivers of cancer and resistance, DNA
damage response and antibody drug conjugates -- and by championing
the development of personalised combinations, AstraZeneca has the
vision to redefine cancer treatment and one day eliminate cancer as a
cause of death.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - respiratory, inflammation, autoimmune
disease (RIA), cardiovascular and metabolic disease (CVMD) and
oncology - as well as in infection and neuroscience. AstraZeneca
operates in over 100 countries and its innovative medicines are used
by millions of patients worldwide. For more information please visit:


Neil Burrows UK/Global +44 7842 350541
Vanessa UK/Global +44 7880 400690
Karen UK/Global +44 7818 524012
Jacob Lund Sweden +46 8 553 260 20
Michele US +1 302 885 2677
Thomas Kudsk +44 7818 524185
Eugenia Litz RIA +44 7884 735627
Nick Stone CVMD, RIA +44 7717 618834
Henry OncologyFinance +44 7788 354619+44 7881 615764
Christer ING, Consensus Forecasts +44 7827 836825
Lindsey Oncology, ING +1 240 543 7970
Mitch Chan Oncology +1 240 477 3771
Dial / Toll +1 866 381 7277

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD -
Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience
and Gastrointestinal


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.